Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing ...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...

Hoth Therapeutics (HOTH) announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide, or ASO, ...

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a ...

Hoth Therapeutics (HOTH) announced that it has received an official Filing Receipt from the United States Patent and Trademark Office for a new ...

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, March 27th.Analysts expect the company to announce ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and ...